Immunocore (IMCR) Competitors $28.33 -0.09 (-0.32%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMCR vs. TGTX, VKTX, BBIO, CRNX, KRYS, ACLX, ADMA, RARE, APLS, and BHVNShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Immunocore (NASDAQ:IMCR) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Do insiders & institutionals believe in IMCR or TGTX? 84.5% of Immunocore shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 9.1% of Immunocore shares are held by insiders. Comparatively, 10.5% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media prefer IMCR or TGTX? In the previous week, Immunocore had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 6 mentions for Immunocore and 4 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 1.31 beat Immunocore's score of 0.61 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in IMCR or TGTX? TG Therapeutics received 593 more outperform votes than Immunocore when rated by MarketBeat users. Likewise, 76.57% of users gave TG Therapeutics an outperform vote while only 72.73% of users gave Immunocore an outperform vote. CompanyUnderperformOutperformImmunocoreOutperform Votes6472.73% Underperform Votes2427.27% TG TherapeuticsOutperform Votes65776.57% Underperform Votes20123.43% Which has more risk and volatility, IMCR or TGTX? Immunocore has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Do analysts recommend IMCR or TGTX? Immunocore currently has a consensus price target of $65.64, indicating a potential upside of 131.69%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 26.29%. Given Immunocore's higher probable upside, research analysts plainly believe Immunocore is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.54TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has stronger valuation and earnings, IMCR or TGTX? TG Therapeutics has lower revenue, but higher earnings than Immunocore. TG Therapeutics is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunocore$296.31M4.78-$55.29M-$0.95-29.82TG Therapeutics$264.79M18.93$12.67M-$0.10-322.00 Is IMCR or TGTX more profitable? TG Therapeutics has a net margin of -5.42% compared to Immunocore's net margin of -15.87%. TG Therapeutics' return on equity of -8.32% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets Immunocore-15.87% -12.84% -5.09% TG Therapeutics -5.42%-8.32%-3.40% SummaryTG Therapeutics beats Immunocore on 12 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42B$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-29.8246.7391.3417.19Price / Sales4.78411.851,117.70116.80Price / CashN/A182.1042.6437.86Price / Book3.823.894.794.78Net Income-$55.29M-$42.21M$120.07M$225.60M7 Day Performance-2.01%-2.14%-1.90%-1.23%1 Month Performance-11.80%4.21%11.45%3.37%1 Year Performance-53.63%18.40%30.63%16.58% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore2.4978 of 5 stars$28.33-0.3%$65.64+131.7%-51.4%$1.42B$296.31M-29.82497Short Interest ↓TGTXTG Therapeutics4.3117 of 5 stars$34.03+6.3%$40.67+19.5%+87.1%$5.30B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2928 of 5 stars$47.23+0.4%$106.75+126.0%+139.8%$5.26BN/A-51.5620Analyst ForecastGap UpBBIOBridgeBio Pharma4.6959 of 5 stars$27.68+0.7%$47.69+72.3%-30.7%$5.23B$217.77M-11.63400CRNXCrinetics Pharmaceuticals4.0687 of 5 stars$54.23+1.1%$70.82+30.6%+55.4%$5.03B$1.04M-14.39210Positive NewsKRYSKrystal Biotech4.5152 of 5 stars$169.99+3.9%$206.67+21.6%+45.9%$4.89B$50.70M92.45229Analyst ForecastACLXArcellx3.1314 of 5 stars$84.01+0.3%$105.93+26.1%+49.1%$4.54B$155.82M-118.03130Positive NewsADMAADMA Biologics3.776 of 5 stars$18.98+2.1%$21.25+12.0%+325.4%$4.49B$382.81M68.32530Positive NewsGap DownRAREUltragenyx Pharmaceutical4.4437 of 5 stars$45.74-0.1%$87.46+91.2%-2.6%$4.22B$434.25M-7.081,276Analyst ForecastNews CoveragePositive NewsAPLSApellis Pharmaceuticals4.563 of 5 stars$33.79+1.8%$49.94+47.8%-39.6%$4.20B$396.59M-16.35702Analyst DowngradeBHVNBiohaven3.7123 of 5 stars$41.49+7.9%$63.00+51.8%-4.4%$4.20B$462.51M-4.11239Analyst Forecast Related Companies and Tools Related Companies TGTX Competitors VKTX Competitors BBIO Competitors CRNX Competitors KRYS Competitors ACLX Competitors ADMA Competitors RARE Competitors APLS Competitors BHVN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMCR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMCR Stock Alerts